Phase 2 N=49 Staccato Alprazolam in Panic Attack
Treatment of Induced Panic Attack
Primary: Number of Participants With Doxapram-induced Panic Attack — 14; 9 Participants — p=0.200
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=39 Therapies for Treatment-Resistant Panic Disorder Symptoms
Panic Disorder
Primary: Change in Panic Disorder Symptoms, Phase 1 (Week 0 - Week 6) — 4.3 Points on a scale — p=0.0000
Phase 2 N=180 Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder
Panic Disorder
Primary: Panic Disorder Severity Scale (PDSS) — 13.30; 13.37; 7.98; 8.32 units on a scale
Phase 3 N=201 Comparison of Psychotherapy Programs to Treat Panic Disorder
Anxiety Disorders · Panic Disorder · Agoraphobia
Primary: Panic Disorder Severity Scale — 6.72; 5.78; 7 score on a scale — p=>0.16
Phase 2 N=83 Safety and Efficacy of HB-1 for Panic Disorder
Panic Disorder
Primary: Incidence of Treatment-Emergent Adverse Events — 23; 15 Participants
Phase 1 N=20 A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms
Healthy
Primary: Maximum Change From Baseline in Panic Symptom Scale (PSS) Sum Intensity Score — 22.639; 29.944 Score on a scale
Phase 4 N=150 Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment
Panic Disorder
Primary: Participants´Endpoint Change From Baseline in Hamilton Anxiety Rating Scale — 22.59; 22.73 Units on a scale — p=<0.001
N/A N=40 Relaxation Treatment for Anxiety in Adults Aged 60 or Older
Anxiety Disorders
Primary: Change in Anxiety Symptoms — 17.95; 26.2 score on a scale
N/A N=77 Internet-based Self-help Treatment for Panic Disorder: Two Ways of Complementary Psychological Support
Panic Disorder
Primary: Change From Baseline Score in the Panic Disorder Severity Scale at 8 Weeks and 6 Months. — 15.29; 15.75; 13.08; 10.42 units on a scale (range= 0-28) — p=0.05
Phase 4 N=37 Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack
Posttraumatic Stress Disorder
Primary: Clinician Administered PTSD Scale (CAPS) — 72.6; 65.4; 40.7; 49.0 units on a scale — p=.01
Phase 3 N=81 Psychosocial and Medication Treatment for Anxiety in Alcoholism
Alcohol-Related Disorders · Anxiety Disorders
Primary: Clinical Global Impression Scale-I (CGI-I) — 3.65; 3.81; 3.86; 4.05 units on a scale
Phase 4 N=1,004 Primary Care Intervention Strategy for Anxiety Disorders
Post-traumatic Stress Disorder · Generalized Anxiety Disorder · Panic Disorder
Primary: BSI-12 (Anxiety and Somatization Subscales) — 325; 258 number of responders
Phase 4 N=17 The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder
Panic Disorder
Primary: Panic Disorder Severity Scale (PDSS) — 9.13 units on a scale
Phase 4 N=418 Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
Generalized Anxiety Disorder · Panic Disorder
Primary: Cumulative Percent of Participants Showing a Response in the Symptoms of Anxiety (Decrease in Total Hamilton Anxiety (HAM-A) -Score of >=50%) in the Intent-to-treat…
Phase 3 N=224 PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge
Social Anxiety Disorder
Primary: Subjective Units of Distress Scale (SUDS) Score — 77.7; 78.2; 62.3; 61.3 score on a scale — p=.5063
Phase 2 N=41 PH94B in the Treatment of Adjustment Disorder With Anxiety
Adjustment Disorder With Anxious Mood
Primary: Hamilton Anxiety Scale (HAM-A) Score — -12.5; -12.6 score on a scale — p=0.9338
Early Phase 1 N=53 Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine
Nicotine Addiction · Panic Attack
Primary: Smoking Abstinence — 8.25; 12.35 percentage of participants
N/A N=69 Using the Canary Breathing System for Panic Disorder Patients
Panic Disorder
Primary: Percent of Subjects Achieving a 40% Decrease in Overall PDSS Score (Clinically Significant Response) — 33 Participants
Phase 4 N=321 A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder
Panic Disorder
Primary: Mean Change From Baseline in Panic and Agoraphobia Scale (PAS) Total Score at the End of Treatment Phase — -17.4; -17.0 Scores on scale
Phase 3 N=61 Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
Social Anxiety Disorder
Primary: Liebowitz Social Anxiety Scale (LSAS) — 7.77; 7.84 units on a scale — p=.267
Phase 2 N=69 Combined Treatment for Generalized Anxiety Disorder (GAD)
Generalized Anxiety Disorder
Primary: Hamilton Anxiety Rating Scale (HAM-A) — 25.9; 23.8; 20.9; 19.4 units on a scale — p=.17
Phase 2 N=25 Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression
Panic Disorder · Major Depressive Disorder
Primary: Panic Disorder Severity Scale (PDSS) — 6; 1 responders
Phase 4 N=26 A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients
Panic Disorder
Primary: Change in Mean Total Panic Disorder Severity Scale (PDSS) Scores — -5.3; -5.6 units on a scale
Phase 4 N=42 Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly
Generalized Anxiety Disorder
Primary: Comparisons of End of Study HAM-A Score Means for Sertraline 50 mg vs Placebo, Sertraline 100 mg vs Placebo, and Sertraline 50 mg vs. Sertraline 100 mg — 10.638; 10.008…
N/A N=68 Exposure Therapy For Veterans With PTSD And Panic Attacks
PTSD · Panic Attacks
Primary: Change in PTSD Symptoms (CAPS) Between MCET-V and CPT Groups — 81.8; 80.5; 67.8; 68.1 units on a scale — p=0.30
N/A N=53 LUCHAR - Latinos Using Counseling for Help With Asthma and Anxiety Reduction
Asthma · Panic Disorder
Primary: Change in Severity of Panic Disorder as Measured by the Panic Disorder Severity Scale — 2.17; 2.40; 1.64; 1.52 score on a scale
Phase 3 N=511 Experimental Medication For the Treatment of Generalized Anxiety Disorder
Anxiety Disorder
Primary: Change in HAM-A Total Score — -12.9; -15.7; -12.5 Units on a Scale — p=0.6540
Phase 4 N=3 The Role of Orexin in Human Panic Disorder
Panic Disorder
Primary: Change in Orexin Levels (Blood) +1 Minute
Phase 4 N=19 Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome
Anticholinergics Toxicity
Primary: Comparison of RASS Score Between Physostigmine and Lorazepam: Before Bolus — 1.5; 1 score on a scale
N/A N=80 Inhalation Intervention for Nausea in the Emergency Department
Nausea · Vomiting
Primary: Nausea Verbal Numerical Rating Scale (0-10) at 10 Minutes Post Intervention — 3; 6 VNRS